Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Concern over SREs rises with increasing incidence of metastatic RCC

Umer M et al. Ann Med Surg. 2018 Jan 21. doi: 10.1016/j.amsu.2018.01.002

Publish date:: August 24, 2018

Key clinical point: As the incidence of metastatic renal cell carcinoma (RCC) continues to rise, knowledge of skeletal-related events and appropriate interventions is essential.

Major finding: About 85% of patients with metastatic RCC experience skeletal-related events and associated complications.

Study details: A literature review of skeletal metastasis in RCC.

Disclosures: The study did not receive specific funding.

Read the article.

Citation:

Umer M et al. Ann Med Surg. 2018 Jan 21. doi: 10.1016/j.amsu.2018.01.002

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,